Skip to content
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact
OmniAb
  • About
    • Overview
    • Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Antigen Design
    • Antibody Generation
      • OmniRat
      • OmniMouse
      • OmniChicken
      • OmniTaur
      • Bispecific Platforms
    • Screening
      • GEM
      • xPloration
    • Antibody Optimization
    • Ion Channel and Transporter Technology
    • Scientific Publications
  • Partnerships
    • Overview
    • Why Partner with OmniAb?
    • Partner Pipeline
    • Contact Business Development
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Stock Info
    • SEC Filings
    • Governance
      • Governance Documents
      • Executive Officers
      • Board of Directors
      • Board Committees
    • Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts
  • Contact

OmniRat® & OmniFlic®: Transgenic rodents for human antibody discovery

  • Antibody Generation
  • OmniRat
  • OmniMouse
  • OmniChicken
  • OmniTaur
  • Bispecific Platforms

The only human Ig-transgenic rats for the discovery of therapeutic antibodies

OmniRat and OmniFlic are the only transgenic rats available for the generation of monospecific and bispecific human antibodies. These animal platforms have been extensively validated and boast a strong record of clinical development success.

About OmniRat

Launched in 2012, OmniRat was the first example of a successful knock-out of the endogenous rat immunoglobulin genes coupled with transgenesis of the human counterparts.

OmniRat produces a diverse repertoire of antibodies with human idiotypes and similar immunological characteristics as rat antibodies from wildtype animals. When cross-reactivity against mouse is required, OmniRat is the first choice as a rodent platform.

OmniRat features:

  • Contains functional recombinant immunoglobulin loci
  • Rearranges functional human Ig genes
  • Uses genes with similar frequency as humans
  • Shows normal human CDR3 length distribution
  • Demonstrates normal B cell development
  • Shows high expression of immunoglobulins
  • Displays normal hypermutation and affinity maturation

OmniFlic: a fixed light-chain variation of OmniRat

The OmniFlic transgenic rat expresses a fixed VK3-15 light chain so different antibodies generated using this platform can be easily combined to form a bispecific human antibody.

Learn About OmniFlic

Scientific Publications

Human antibody expression in transgenic rats: Comparison of chimeric IgH loci with human VH, D and JH but bearing different rat C-gene regions

Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing

About

  • Overview
  • Team
  • Board of Directors
  • Careers

Partnerships

  • Overview
  • Why Partner with OmniAb?
  • Partner Pipeline
  • Contact Business Development

Technology

  • Overview
  • Antigen Design
  • Antibody Generation
  • Screening
  • Antibody Optimization
  • Ion Channel and Transporter Technology
  • Scientific Publications

OmniAb, Inc.
5980 Horton Street
Suite 600
Emeryville, CA 94608

[email protected]
[email protected]

Contact | Privacy Policy | Disclaimer

© 2023 OmniAb, Inc. All rights reserved.